Total Payments
$1.1M
2024 Payments
$54,458
Companies
38
Transactions
1,581
Medicare Patients
4,339
Medicare Billing
$1.7M
Payment Breakdown by Category
Other$578,239 (53.3%)
Consulting$317,679 (29.3%)
Research$76,272 (7.0%)
Travel$66,833 (6.2%)
Food & Beverage$43,332 (4.0%)
Education$1,521 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $473,532 | 204 | 43.7% |
| Consulting Fee | $317,679 | 104 | 29.3% |
| Honoraria | $104,707 | 56 | 9.7% |
| Unspecified | $76,272 | 10 | 7.0% |
| Travel and Lodging | $66,833 | 226 | 6.2% |
| Food and Beverage | $43,332 | 949 | 4.0% |
| Education | $1,521 | 32 | 0.1% |
Payments by Type
General
$1.0M
1,571 transactions
Research
$76,272
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | $243,866 | 330 | $0 (2024) |
| ACADIA Pharmaceuticals Inc | $233,334 | 247 | $0 (2024) |
| Merz Pharmaceuticals, LLC | $106,232 | 54 | $0 (2024) |
| Amneal Pharmaceuticals LLC | $89,249 | 96 | $0 (2024) |
| Acorda Therapeutics, Inc | $84,546 | 78 | $0 (2024) |
| Kyowa Kirin, Inc. | $80,114 | 79 | $0 (2024) |
| MDD US Operations, LLC | $42,246 | 70 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $40,877 | 75 | $0 (2022) |
| US WorldMeds, LLC | $34,276 | 73 | $0 (2020) |
| Merz North America, Inc. | $28,995 | 25 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $54,458 | 150 | MDD US Operations, LLC ($15,170) |
| 2023 | $68,918 | 174 | Merz Pharmaceuticals, LLC ($16,445) |
| 2022 | $166,738 | 165 | Merz Pharmaceuticals, LLC ($77,864) |
| 2021 | $86,960 | 142 | Amneal Pharmaceuticals LLC ($22,174) |
| 2020 | $152,070 | 143 | Amneal Pharmaceuticals LLC ($35,272) |
| 2019 | $172,503 | 268 | Acorda Therapeutics, Inc ($51,577) |
| 2018 | $212,880 | 276 | Teva Pharmaceuticals USA, Inc. ($82,422) |
| 2017 | $169,349 | 263 | ACADIA Pharmaceuticals Inc ($79,284) |
All Payment Transactions
1,581 individual payment records from CMS Open Payments — Page 1 of 64
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | Abbott Laboratories | INFINITY (Device) | Food and Beverage | In-kind items and services | $20.68 | General |
| Category: Neuromodulation | ||||||
| 12/17/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Education | In-kind items and services | $3.40 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 12/16/2024 | Amneal Pharmaceuticals LLC | ONGENTYS (Drug) | Food and Beverage | In-kind items and services | $7.47 | General |
| Category: NEUROLOGY | ||||||
| 12/15/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $28.63 | General |
| Category: Neuropsychiatry | ||||||
| 12/14/2024 | ABBVIE INC. | BOTOX (Biological), QULIPTA | Food and Beverage | In-kind items and services | $6.63 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 12/05/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $59.46 | General |
| 12/05/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $49.78 | General |
| 12/05/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $25.00 | General |
| 12/03/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $650.00 | General |
| 12/03/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Education | In-kind items and services | $3.40 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 11/25/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $15.96 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 11/21/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $21.92 | General |
| Category: PSYCHIATRY | ||||||
| 11/19/2024 | Medtronic, Inc. | PERCEPT PC BRAINSENSE (Device) | Food and Beverage | In-kind items and services | $103.53 | General |
| Category: Deep Brain Neurostimulation | ||||||
| 11/19/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $13.25 | General |
| Category: Central Nervous System | ||||||
| 11/15/2024 | MDD US Operations, LLC | — | Consulting Fee | Cash or cash equivalent | $5,175.00 | General |
| 11/15/2024 | Amneal Pharmaceuticals LLC | CREXONT (Drug) | Education | In-kind items and services | $724.00 | General |
| Category: NEUROLOGY | ||||||
| 11/15/2024 | MDD US Operations, LLC | — | Travel and Lodging | In-kind items and services | $688.96 | General |
| 11/15/2024 | MDD US Operations, LLC | — | Travel and Lodging | In-kind items and services | $247.43 | General |
| 11/15/2024 | MDD US Operations, LLC | — | Travel and Lodging | In-kind items and services | $218.88 | General |
| 11/15/2024 | MDD US Operations, LLC | — | Food and Beverage | In-kind items and services | $202.20 | General |
| 11/15/2024 | MDD US Operations, LLC | — | Food and Beverage | In-kind items and services | $178.63 | General |
| 11/15/2024 | MDD US Operations, LLC | — | Food and Beverage | In-kind items and services | $90.00 | General |
| 11/15/2024 | MDD US Operations, LLC | — | Food and Beverage | In-kind items and services | $73.07 | General |
| 11/15/2024 | MDD US Operations, LLC | — | Food and Beverage | In-kind items and services | $73.07 | General |
| 11/14/2024 | ABBVIE INC. | VYALEV (Drug) | Food and Beverage | In-kind items and services | $26.52 | General |
| Category: NEUROSCIENCE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Period to Investigate the Efficacy and Safety of NT 201 in the Unilateral and Bilateral Treatment of Essential Tremor of the Upper Limb | Merz Pharmaceuticals, LLC | $74,382 | 6 |
| EFFECT OF LY3154207 ON COGNITION IN MILD TO MODERATE PARKINSONS DISEASE DEMENTIA PDD - THE PRESENCE STUDY | Eli Lilly and Company | $1,550 | 1 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $150.00 | 1 |
| A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | Eli Lilly and Company | $114.80 | 1 |
| A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL COMPARING EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS SEMAGLUTIDE ONCE WEEKLY AS ADD-ON THERAPY TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES | Eli Lilly and Company | $75.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 25 | 1,026 | 44,774 | $1.3M | $436,942 |
| 2022 | 23 | 1,016 | 39,284 | $1.2M | $418,365 |
| 2021 | 24 | 1,160 | 45,610 | $1.4M | $474,327 |
| 2020 | 24 | 1,137 | 41,257 | $1.2M | $407,060 |
Total Patients
4,339
Total Services
170,925
Medicare Billing
$1.7M
Procedure Codes
96
All Medicare Procedures & Services
96 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2023 | 33 | 27,590 | $382,397 | $133,308 | 34.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 283 | 686 | $270,727 | $102,747 | 38.0% |
| J0588 | Injection, incobotulinumtoxin a, 1 unit | Office | 2023 | 28 | 13,005 | $149,948 | $52,688 | 35.1% |
| 99483 | Assessment of and care planning for patient with impaired thought processing, typically 60 minutes | Office | 2023 | 139 | 146 | $100,740 | $34,173 | 33.9% |
| J0587 | Injection, rimabotulinumtoxinb, 100 units | Office | 2023 | 12 | 2,310 | $62,670 | $22,864 | 36.5% |
| 64616 | Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | Office | 2023 | 42 | 111 | $77,009 | $19,691 | 25.6% |
| 95874 | Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | Office | 2023 | 57 | 162 | $35,214 | $11,315 | 32.1% |
| 93660 | Evaluation of heart function using tilt table | Office | 2023 | 60 | 60 | $34,360 | $8,347 | 24.3% |
| 64644 | Injection of chemical for paralysis of nerve muscles on arm or leg, 5 or more muscles, first extremity | Office | 2023 | 19 | 60 | $29,248 | $7,829 | 26.8% |
| 64646 | Injection of chemical for paralysis of nerve muscles on trunk, 1-5 muscles | Office | 2023 | 43 | 96 | $44,400 | $7,179 | 16.2% |
| 64611 | Injection of chemical for paralysis of salivary glands on both sides of mouth | Office | 2023 | 29 | 57 | $20,577 | $4,751 | 23.1% |
| 95984 | Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, each additional 15 minutes with qualified health professional | Office | 2023 | 19 | 120 | $17,310 | $4,674 | 27.0% |
| 99487 | Complex chronic care management services for two or more chronic conditions, first 60 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 21 | 39 | $10,608 | $4,661 | 43.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 21 | 21 | $10,843 | $3,844 | 35.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 29 | 30 | $8,985 | $3,391 | 37.7% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 19 | 22 | $5,742 | $2,441 | 42.5% |
| 64642 | Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, first extremity | Office | 2023 | 12 | 27 | $11,838 | $2,345 | 19.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 23 | 28 | $6,125 | $2,322 | 37.9% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 22 | 25 | $4,525 | $1,908 | 42.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 31 | 34 | $4,816 | $1,760 | 36.5% |
| 95983 | Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | Office | 2023 | 19 | 40 | $6,500 | $1,749 | 26.9% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 29 | 56 | $4,861 | $1,592 | 32.8% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 12 | 15 | $2,130 | $852.00 | 40.0% |
| 95970 | Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator | Office | 2023 | 12 | 21 | $2,829 | $340.00 | 12.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 12 | 13 | $897.00 | $170.82 | 19.0% |
About Fernando Pagan
Fernando Pagan is a Neurology healthcare provider based in Washington, District of Columbia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/12/2005. The National Provider Identifier (NPI) number assigned to this provider is 1881682029.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Fernando Pagan has received a total of $1.1M in payments from pharmaceutical and medical device companies, with $54,458 received in 2024. These payments were reported across 1,581 transactions from 38 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($473,532).
As a Medicare-enrolled provider, Pagan has provided services to 4,339 Medicare beneficiaries, totaling 170,925 services with total Medicare billing of $1.7M. Data is available for 4 years (2020–2023), covering 96 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Washington, DC
- Active Since 10/12/2005
- Last Updated 03/14/2012
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1881682029
Products in Payments
- NUPLAZID (Drug) $233,334
- AUSTEDO (Drug) $214,706
- Xeomin (Biological) $100,866
- INBRIJA (Drug) $91,205
- RYTARY (Drug) $59,345
- NOURIANZ (Drug) $56,222
- GOCOVRI (Drug) $29,266
- XEOMIN (Biological) $25,995
- MYOBLOC (Biological) $21,132
- Nourianz (Drug) $20,824
- NORTHERA (Drug) $16,538
- SD809-HD (Drug) $10,217
- Austedo XR (Drug) $10,084
- Duopa (Drug) $9,889
- LATUDA (Drug) $8,734
- Xadago (Drug) $7,940
- CREXONT (Drug) $7,602
- SD809-TD (Drug) $7,585
- INGREZZA (Drug) $7,262
- ONGENTYS (Drug) $6,027
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Washington
Dr. Laxman Bahroo, D.o,, D.O,
Neurology — Payments: $3.4M
Neurology $3.4M
Dr. Fahd Amjad, Md, MD
Neurology — Payments: $2.4M
Neurology $2.4M
Jessica Ailani, Md, MD
Neurology — Payments: $1.3M
Neurology $1.3M
Dr. Yasar Torres-Yaghi, M.d, M.D
Neurology — Payments: $868,293
Neurology $868,293
Benjamin Osborne
Neurology — Payments: $770,154
Neurology $770,154
Dr. Faria Amjad, Md, MD
Neurology — Payments: $671,517
Neurology $671,517